ライフサイエンスコーパス: reflux disease

1 s associated with a risk of gastroesophageal reflux disease.

2 in pediatric patients with gastroesophageal reflux disease.

3 r the surgical treatment of gastroesophageal reflux disease.

4 formed surgical therapy for gastroesophageal reflux disease.

5 vel potential treatment for gastroesophageal reflux disease.

6 ently overlap with those of gastroesophageal reflux disease.

7 cribed for the treatment of gastroesophageal reflux disease.

8 ormation, 11 (41%) had objective evidence of reflux disease.

9 the presence of concomitant gastroesophageal reflux disease.

10 vely distinguishing it from gastroesophageal reflux disease.

11 an effective treatment for gastroesophageal reflux disease.

12 ognized disease that mimics gastroesophageal reflux disease.

13 rritable bowel syndrome and gastroesophageal reflux disease.

14 squamous mucosa damaged by gastroesophageal reflux disease.

15 developing complications of gastroesophageal reflux disease.

16 ease commonly confused with gastroesophageal reflux disease.

17 disorders and treatment of gastroesophageal reflux disease.

18 between BMI and symptoms of gastroesophageal reflux disease.

19 iologic system is perturbed in subjects with reflux disease.

20 ccurrence and management of gastroesophageal reflux disease.

21 s are at increased risk for gastroesophageal reflux disease.

22 dicative of severe types of gastroesophageal reflux disease.

23 ts with symptomatic GERD do not have erosive reflux disease.

24 and a reliable indicator of gastroesophageal reflux disease.

25 e research and treatment of gastroesophageal reflux disease.

26 l ulcer, gastric ulcer, and gastroesophageal reflux disease.

27 esophagus or other types of gastroesophageal reflux disease.

28 commonly associated with gastro-oesophageal reflux disease.

29 evant to the association between obesity and reflux disease.

30 to those of patients with gastro-oesophageal reflux disease.

31 heartburn in patients with gastro-esophageal reflux disease.

32 ure by waist belt on reflux in patients with reflux disease.

33 o clear and buffer the refluxate, leading to reflux disease.

34 lications or recurrence of gastro-esophageal reflux disease.

35 long-lasting treatment for gastroesophageal reflux disease.

36 5%), constipation (13%) and gastroesophageal reflux disease (12%).

37 , hypertension (21.9%), and gastroesophageal reflux disease (17.3%).

38 The presence of gastroesophageal reflux disease (26%), esophageal stricture (39%), or bot

39 nusitis 42.3% (5870), and gastro-oesophageal reflux disease 39.3% (5650).

40 0%), sinusitis (47.8%), and gastroesophageal reflux disease (46.3%).

41 pnea may be associated with gastroesophageal reflux disease, a strong risk factor for Barrett's esoph

42 , chronic rhinitis, asthma, gastroesophageal reflux disease, adenotonsillitis, sleep apnea, anxiety,

43 factors evaluated included gastroesophageal reflux disease, alcohol consumption, smoking, chronic op

44 a complication of chronic gastro-oesophageal reflux disease, although asymptomatic individuals might

45 ased abdominal pressure and gastroesophageal reflux disease, although this pathogenic mechanism has n

46 and duration of symptoms of gastroesophageal reflux disease among randomly selected participants in t

47 -nine subjects were identified as nonerosive reflux disease and 17 as erosive esophagitis.

48 quality of life related to gastroesophageal reflux disease and a 50% or greater reduction in the use

49 of peptic ulcer disease and gastrosophageal reflux disease and acts by irreversibly blocking ATP4A,

50 ecreased prevalence of both gastroesophageal reflux disease and adenocarcinoma of the esophagus and c

51 The incidence of gastro-oesophageal reflux disease and Barrett's oesophagus is increasing.

52 nd a higher prevalence of gastro-oesophageal reflux disease and blistering/desquamating skin disorder

53 niques in the management of gastroesophageal reflux disease and constipation also may have an impact

54 psies of patients with EoE, gastroesophageal reflux disease and controls.

55 ted with conditions such as gastroesophageal reflux disease and diabetes mellitus, as well as emergen

56 ties is similar except for gastro-esophageal reflux disease and dyslipidemia that appear to be more s

57 both procedures except for gastro-esophageal reflux disease and dyslipidemia, which were more success

58 ged 18 years and older with gastroesophageal reflux disease and erosive esophagitis.

59 evolving definition and its relationship to reflux disease and functional gastrointestinal disorders

60 osis, including the role of gastroesophageal reflux disease and proton pump inhibitor-responsive esop

61 e to design new surgical strategies to treat reflux disease and reduce complications of fundoplicatio

62 The potential roles of undiagnosed venous reflux disease and the military physical training enviro

63 Approximately 20% have gastro-oesophageal reflux disease and this can be effectively treated with

64 n with a medical history of gastroesophageal reflux disease and type II diabetes presented to the hos

65 of dyspnea, 87 percent had gastroesophageal reflux disease, and 54 percent had nasal congestion.

66 eep-disordered breathing, gastro-oesophageal reflux disease, and anxiety or depression.

67 ma, mechanical ventilation, gastroesophageal reflux disease, and aspiration or other types of pneumon

68 ological manifestation of gastro-oesophageal reflux disease, and is a major risk factor for the devel

69 r diagnoses (eg, pneumonia, gastroesophageal reflux disease, and other comorbidities).

70 o irritable bowel syndrome, gastroesophageal reflux disease, and peptic ulcer disease.

71 isk factor for oesophageal adenocarcinoma is reflux disease, and the rising incidence of this coincid

72 is usually due to asthma, gastro-oesophageal reflux disease, and upper airway conditions, and that it

73 lved in the pathogenesis of gastroesophageal reflux disease are complex and multifactorial.

74 ation rate and incidence of gastroesophageal reflux disease are concerning.

75 pharmacologic strategies in the treatment of reflux disease are highlighted.

76 nd has focused attention on gastroesophageal reflux disease as a causative factor in this shift.

77 f gastric disorders such as gastroesophageal reflux disease, autoimmune gastritis, gastric cancer, an

78 have been identified-mainly gastroesophageal reflux disease, Barrett's esophagus, obesity, and tobacc

79 assessed 100 patients with gastroesophageal reflux disease before and after sphincter augmentation.

80 e and effective therapy for gastroesophageal reflux disease, but its effect on the LES has not been e

81 s frequently mimic those of gastroesophageal reflux disease, but the diseases are distinct in their h

82 of a confirmed diagnosis of gastroesophageal reflux disease by an abnormal esophageal pH study (body

83 ar-old men with symptoms of gastroesophageal reflux disease by Cytosponge is cost effective and would

84 that is distinguished from gastroesophageal reflux disease by the expression of a unique esophageal

85 r place in the treatment of gastroesophageal reflux disease can be determined.

86 acid entering the mouth in gastro-esophageal reflux disease can cause dental erosion.

87 e been confirmed in EoE and gastroesophageal reflux disease cell cultures.

88 Risk factors include gastroesophageal reflux disease, central obesity, and smoking.

89 Gastroesophageal reflux disease complicated by Barrett esophagus (BE) is

90 Gastroesophageal reflux disease complicated by Barrett's esophagus (BE) i

91 se of these technologies in gastroesophageal reflux disease continues to accelerate, and the last 2 y

92 nterval [CI]: 1.04-2.67) or gastroesophageal reflux disease controls (OR = 1.61; 95% CI: 1.33-1.96).

93 oesophageal reflux disease (gastroesophageal reflux disease controls, n = 1332), and population-based

94 chest pain associated with gastroesophageal reflux disease, correlates abnormal ambulatory pH monito

95 , regurgitation, dysphagia, gastroesophageal reflux disease, cough, aspiration, laryngitis, GERD, GOR

96 , regurgitation, dysphagia, gastroesophageal reflux disease, cough, aspiration, laryngitis, GERD, GOR

97 ssive surgical treatment of gastroesophageal reflux disease decreases the rate of bronchiolitis and i

98 rugs (lipid-lowering drugs, gastroesophageal reflux disease drugs, antihypertensive drugs, sleep aids

99 sses (lipid-lowering drugs, gastroesophageal reflux disease drugs, diabetes drugs, antihypertensive d

100 as functional dyspepsia and gastroesophageal reflux disease (e.g. vomiting, disordered lower esophage

101 n the last 2 years for many gastroesophageal reflux disease endotherapies, providing some insight int

102 e (NERD) compared with patients with erosive reflux disease (ERD) or Barrett's esophagus (BE).

103 onse rates compared to patients with erosive reflux disease (ERD); pH metry contributes to GERD diagn

104 l complications of obesity: gastroesophageal reflux disease, erosive esophagitis, Barrett's esophagus

105 Most patients with gastroesophageal reflux disease experience symptomatic relapse after stop

106 In both erosive and non-erosive reflux disease, expression levels of Occludin and ZO-1,-

107 ides a clinical overview of gastroesophageal reflux disease, focusing on diagnosis, treatment, and pr

108 th those from subjects with gastroesophageal reflux disease (gastroesophageal reflux disease controls

109 e interval [CI], 2.9-12.9), gastroesophageal reflux disease (GERD) (RR, 1.9; 95% CI, 1.4-2.6), dyspep

110 thophysiological factor in gastro-esophageal reflux disease (GERD) and as a target for GERD treatment

111 ghrelin are associated with gastroesophageal reflux disease (GERD) and Barrett's esophagus.

112 incidence and predictors of gastroesophageal reflux disease (GERD) and dyspepsia and their associatio

113 hageal disorders, including gastroesophageal reflux disease (GERD) and eosinophilic esophagitis (EoE)

114 ner to the understanding of gastroesophageal reflux disease (GERD) and its complications.

115 an alternative treatment of gastroesophageal reflux disease (GERD) and may provide durable reflux con

116 ential for the treatment of gastroesophageal reflux disease (GERD) and other esophagogastric diseases

117 the Montreal definition of gastroesophageal reflux disease (GERD) and the Rome III definition of fun

118 sophageal manifestations of gastroesophageal reflux disease (GERD) and to compare the most recent tec

119 recipients with documented gastroesophageal reflux disease (GERD) are at increased risk for graft dy

120 urrent diagnostic tests for gastroesophageal reflux disease (GERD) are suboptimal and do not accurate

121 ia who were thought to have gastroesophageal reflux disease (GERD) but who did not respond to medical

122 Management of gastroesophageal reflux disease (GERD) commonly starts with an empiric tr

123 a minority of patients with gastroesophageal reflux disease (GERD) develop Barrett's esophagus.

124 d; 70% had been treated for gastroesophageal reflux disease (GERD) during infancy.

125 However, gastroesophageal reflux disease (GERD) has remained the most common esoph

126 variable rates of recurrent gastroesophageal reflux disease (GERD) have been reported.

127 iding physicians diagnose gastro-oesophageal reflux disease (GERD) have not been evaluated in terms o

128 anges associated with acute gastroesophageal reflux disease (GERD) have not been studied prospectivel

129 r pH monitoring documented Gastro-Esophageal Reflux Disease (GERD) in 53.4% of patients.

130 The prevalence of gastroesophageal reflux disease (GERD) in Africa is not known but is beli

131 as to compare recurrence of gastroesophageal reflux disease (GERD) in children randomized to laparosc

132 ly used in the treatment of gastroesophageal reflux disease (GERD) in children; however, their effica

133 cation for the treatment of gastroesophageal reflux disease (GERD) in comparison with a sham procedur

134 Information about gastro-oesophageal reflux disease (GERD) in patients with Diabetes mellitus

135 Symptoms of gastro-esophageal reflux disease (GERD) in pregnancy are reported with a p

136 se or eliminate features of gastroesophageal reflux disease (GERD) in some patients whose symptoms pe

137 w data on the prevalence of gastroesophageal reflux disease (GERD) in the United States.

138 Gastroesophageal reflux disease (GERD) increases EAC risk, but whether an

139 Gastroesophageal reflux disease (GERD) is a chronic disorder that affects

140 Gastroesophageal reflux disease (GERD) is a common comorbidity among pati

141 Gastroesophageal reflux disease (GERD) is a common diagnosis in infants a

142 Gastrointestinal reflux disease (GERD) is a common disorder that negative

143 Gastroesophageal reflux disease (GERD) is a common medical problem in the

144 Gastroesophageal reflux disease (GERD) is a risk factor for adenocarcinom

145 It has been suggested that gastroesophageal reflux disease (GERD) is a risk factor for developing rh

146 Gastroesophageal reflux disease (GERD) is a very common disorder that aff

147 Gastroesophageal reflux disease (GERD) is associated with impaired epithe

148 Endoscopic management of gastroesophageal reflux disease (GERD) is being employed increasingly.

149 Gastroesophageal reflux disease (GERD) is caused by gastric acid entering

150 The pathogenesis of gastroesophageal reflux disease (GERD) is complex and involves changes in

151 Gastroesophageal reflux disease (GERD) is defined by recurrent and troubl

152 he Montreal classification, gastroesophageal reflux disease (GERD) is much more than heartburn and pa

153 Gastroesophageal reflux disease (GERD) is prevalent worldwide, particular

154 I) therapy in patients with gastroesophageal reflux disease (GERD) is reported in up to 40%.

155 Gastro-esophageal reflux disease (GERD) is suggested to be associated with

156 Gastroesophageal reflux disease (GERD) is the most common gastrointestina

157 Gastroesophageal reflux disease (GERD) is the most prevalent gastrointest

158 Gastroesophageal reflux disease (GERD) is the strongest known risk factor

159 iteria included symptoms of gastroesophageal reflux disease (GERD) more than once a month, use of med

160 Many individuals with gastroesophageal reflux disease (GERD) never visit their general practiti

161 cid peptic disorder such as gastroesophageal reflux disease (GERD) nor should it preclude a diagnosis

162 y used for the treatment of gastroesophageal reflux disease (GERD) or completing Heller's myotomy and

163 Refractory gastroesophageal reflux disease (GERD) reduces quality of life and create

164 Treatment-refractory gastro-oesophageal reflux disease (GERD) remains a significant problem in t

165 Most patients with gastroesophageal reflux disease (GERD) report that stress exacerbates the

166 Gastroesophageal reflux disease (GERD) seems to increase the risk of lary

167 ed for use in patients with gastroesophageal reflux disease (GERD) symptoms despite proton pump inhib

168 ects a higher prevalence of gastroesophageal reflux disease (GERD) symptoms or a higher degree of eso

169 ity of NBI in patients with gastroesophageal reflux disease (GERD) symptoms.

170 The prevalence of gastro-esophageal reflux disease (GERD) varies widely around the world.

171 Patients with gastroesophageal reflux disease (GERD) who are not responding to proton p

172 re matched to subjects with gastroesophageal reflux disease (GERD) without Barrett's esophagus and to

173 f objective measurements of gastroesophageal reflux disease (GERD) would improve management of patien

174 ia, 1.8; constipation, 3.9; gastroesophageal reflux disease (GERD), 9.7.

175 Gastroesophageal reflux disease (GERD), a condition commonly encountered

176 ease (CrD), celiac disease, gastroesophageal reflux disease (GERD), and eosinophilic esophagitis (EoE

177 table bowel syndrome (IBS), gastroesophageal reflux disease (GERD), and overactive bladder syndrome (

178 ysfunction syndrome (RUDS), gastroesophageal reflux disease (GERD), and rare cases of inflammatory pu

179 r three common indications: gastroesophageal reflux disease (GERD), Barrett's esophagus (BE), and non

180 proposed for patients with gastroesophageal reflux disease (GERD), but there is little evidence of i

181 pylori may protect against gastrointestinal reflux disease (GERD), but these results could be due to

182 appraise the prevalence of gastroesophageal reflux disease (GERD), esophagitis, and Barrett's esopha

183 Gastroesophageal reflux disease (GERD), functional dyspepsia (FD) and irr

184 ysiological states, such as gastroesophageal reflux disease (GERD), functional dyspepsia and, possibl

185 tion of body mass index and gastroesophageal reflux disease (GERD), including its complications (esop

186 sophagus, a complication of gastroesophageal reflux disease (GERD), predisposes patients to esophagea

187 previous fundoplication for gastroesophageal reflux disease (GERD), underwent reoperative surgery.

188 f frequency and duration of gastroesophageal reflux disease (GERD), using data from a randomly select

189 Gastroesophageal reflux disease (GERD), which leads to acid reflux into t

190 Unlike gastroesophageal reflux disease (GERD), whose symptoms closely overlap wi

191 ave a similar prevalence of gastroesophageal reflux disease (GERD), yet esophageal adenocarcinoma (EA

192 rease of 50% or more in the Gastroesophageal Reflux Disease (GERD)-Health Related Quality of Life sco

193 eatment-naive patients with gastroesophageal reflux disease (GERD).

194 mplications, postoperative gastro-esophageal reflux disease (GERD).

195 for diagnosing adults with gastroesophageal reflux disease (GERD).

196 ology-based definitions of gastro-esophageal reflux disease (GERD).

197 medical disorders including gastroesophageal reflux disease (GERD).

198 diagnosis and management of gastroesophageal reflux disease (GERD).

199 estinal disorders (FGD) and gastroesophageal reflux disease (GERD).

200 opy-based interventions for gastroesophageal reflux disease (GERD).

201 crease in the prevalence of gastroesophageal reflux disease (GERD).

202 has centered on surgery for gastroesophageal reflux disease (GERD).

203 esophageal manifestation of gastroesophageal reflux disease (GERD).

204 r the surgical treatment of gastroesophageal reflux disease (GERD).

205 report typical symptoms of gastroesophageal reflux disease (GERD).

206 as altered in patients with gastroesophageal reflux disease (GERD).

207 ilic esophagitis (EoE), and gastroesophageal reflux disease (GERD).

208 s omeprazole monotherapy in gastroesophageal reflux disease (GERD).

209 (CNF) for the treatment of gastroesophageal reflux disease (GERD).

210 tory drugs) and symptoms of gastroesophageal reflux disease (GERD).

211 r patients with early-stage gastroesophageal reflux disease (GERD).

212 ice for obese patients with gastroesophageal reflux disease (GERD).

213 r both BE and EA is chronic gastroesophageal reflux disease (GERD).

214 were dysphagia (70.1%) and gastroesophageal reflux disease (GERD)/heartburn (27.1%).

215 o included 10 patients with gastroesophageal reflux disease (GERD; age, 32-60 y; 7 women) without tro

216 ere matched to persons with gastroesophageal reflux disease (GERD; n = 316) and to population control

217 apy in patients with proven gastroesophageal reflux disease [GERD]), to document physiologic levels o

218 ntified domains (dysphagia, gastroesophageal reflux disease [GERD], nausea/vomiting, and pain) align

219 Gastroesophageal reflux disease (GORD) is a chronic and a common conditio

220 Although gastro-oesophageal reflux disease (GORD) is a common medical complaint, the

221 toms and the aetiology of gastro-oesophageal reflux disease (GORD) remains unclear.

222 lastic progression in the gastro-oesophageal reflux disease (GORD)-Barrett's metaplasia (BM)-oesophag

223 patients with symptomatic gastro-oesophageal reflux disease (GORD).

224 in pediatric patients with gastroesophageal reflux disease have shown good to excellent results; how

225 in patients with normal GE (Gastroesophageal Reflux Disease Health-Related Quality of Life score 18.2

226 mptom that can be caused by gastroesophageal reflux disease; however, treatment outcome has been diff

227 c antireflux surgery due to gastroesophageal reflux disease in adults (>18 years).

228 associated with symptoms of gastroesophageal reflux disease in both normal-weight and overweight wome

229 correlations of BE/EA with gastroesophageal reflux disease in male individuals and obesity in female

230 in meters - and symptoms of gastroesophageal reflux disease in persons of normal weight has not been

231 cidic environment caused by gastroesophageal reflux disease in the gastroesophageal junction and asso

232 ic approach to patients with extraesophageal reflux disease involved the use of insensitive tools, wh

233 Extraesophageal reflux disease is a common clinical presentation to gast

234 Gastroesophageal reflux disease is a common clinical problem.

235 Gastroesophageal reflux disease is a highly prevalent chronic condition i

236 Gastroesophageal reflux disease is a highly prevalent disease.

237 Gastro-oesophageal reflux disease is a potential risk factor for the develo

238 Gastroesophageal reflux disease is a prevalent disorder that often requir

239 the pathogenesis of heartburn in nonerosive reflux disease is a reaffirmation of the definition of r

240 Gastroesophageal reflux disease is common in adults of all ages, but its

241 Antireflux surgery for gastro-esophageal reflux disease is followed by varying rates of re-interv

242 hagus epithelium related to gastroesophageal reflux disease, is the strongest known risk factor for t

243 ough heartburn is the most common symptom of reflux disease, it is unclear whether the severity of he

244 on "Endoscopic Therapy for Gastroesophageal Reflux Disease." It was approved by the Clinical Practic

245 apies have emerged to treat gastroesophageal reflux disease itself.

246 s (asthma, sinusitis, and gastro-oesophageal reflux disease), mental health disorders (depression, po

247 for an esophageal etiology-gastroesophageal reflux disease, motility abnormalities, or esophageal hy

248 rcinogen treatment leads to gastroesophageal reflux disease, multilayered epithelium (MLE, a presumed

249 lication for PPI-refractory gastroesophageal reflux disease (n = 14 270 degrees LPF vs. n = 28 360 de

250 ere matched to persons with gastroesophageal reflux disease (n = 308) without Barrett's esophagus and

251 indeterminate EoE (n = 15), gastroesophageal reflux disease (n = 7), or normal esophagus (n = 21).

252 symptom control in patients with non-erosive reflux disease (NERD) after 6 months.

253 t symptom burden in patients with nonerosive reflux disease (NERD) compared with patients with erosiv

254 Patients with non erosive reflux disease (NERD) have lower response rates compared

255 To analyse the concept of nonerosive reflux disease (NERD), examining its evolving definition

256 h improved understanding of gastroesophageal reflux disease, newer developments in diagnostic techniq

257 , including rhinosinusitis, gastroesophageal reflux disease, obesity and dysfunctional breathing.

258 cter (LES) in patients with gastroesophageal reflux disease often has a low resting pressure and a sh

259 orically distinguished from gastroesophageal reflux disease on the basis of histology and lack of res

260 hen excluding patients with gastrointestinal reflux disease or functional dyspepsia.

261 indeterminate EoE) but not gastroesophageal reflux disease or normal esophagus and was correlated to

262 apy in patients with severe gastroesophageal reflux disease or the Zollinger-Ellison syndrome.

263 ry of peptic ulcer disease, gastroesophageal reflux disease, or gastrointestinal bleeding, and prior

264 This article is a review of gastroesophageal reflux disease, other types of esophagitis, benign and m

265 le score <9 (p = .021), and gastroesophageal reflux disease (p = .033).

266 We randomly assigned 64 gastroesophageal reflux disease patients to radiofrequency energy deliver

267 on for selected symptomatic gastroesophageal reflux disease patients who are intolerant of, or desire

268 Too much acid can lead to gastroesophageal reflux disease, peptic ulcer disease, and stress-related

269 eosinophilic bronchitis, gastro-oesophageal reflux disease, postnasal drip syndrome or rhinosinusiti

270 a >50% improvement in their gastroesophageal reflux disease quality of life score (n = 19 [61%] vs. n

271 of GERD was by means of the gastroesophageal reflux disease questionnaire (GERDQ) while the diagnosis

272 objective is to evaluate the ability of the Reflux Disease Questionnaire (RDQ) to identify GERD acco

273 ary outcome was symptom control evaluated by Reflux Disease Questionnaire and Reflux Symptom Index.

274 symptoms where based on the use of validated reflux-disease questionnaire (RDQ).

275 Endoscopic therapies for gastroesophageal reflux disease represent a minimally invasive alternativ

276 vely high rate of recurrent gastroesophageal reflux disease requiring treatment, diminishing some of

277 f non-drug treatments for gastro-oesophageal reflux disease, safety of long-term drug treatment, and

278 igated whether patients with supraesophageal reflux disease (SERD) have impaired UES and esophageal b

279 ence of anxiety, headaches, gastroesophageal reflux disease, sleep apnea, and infections of the respi

280 fied version of a validated gastroesophageal reflux disease-specific QOL tool to patients before and

281 ty of life, measured by the gastroesophageal reflux disease-specific QOL tool, and recurrence, define

282 ) had objective findings of gastroesophageal reflux disease, such as esophagitis.

283 proved in group A, with the Gastroesophageal Reflux Disease Symptom Assessment Scale score decreasing

284 very significantly improved gastroesophageal reflux disease symptoms and quality of life compared wit

285 ue in patients with chronic gastroesophageal reflux disease symptoms is of unproven value, and recomm

286 y for patients with chronic gastroesophageal reflux disease symptoms to assess for Barrett's esophagu

287 d Kingdom with histories of gastroesophageal reflux disease symptoms, assuming the prevalence of Barr

288 Triggered by gastroesophageal reflux disease, the origin of this metaplasia remains un

289 pertension, hyperlipidemia, gastroesophageal reflux disease, thyroid disease, diabetes, osteoporosis)

290 tly cleared new endoluminal gastroesophageal reflux disease treatments; however, no controlled trials

291 The history of gastroesophageal reflux disease was highly prevalent in patients who deve

292 Gastroesophageal reflux disease was identified as an important risk facto

293 De novo gastroesophageal reflux disease was reported in 43.8%.

294 r patients with symptomatic gastroesophageal reflux disease were older (58 for men and 64 for women)

295 tis, allergic rhinitis, and gastroesophageal reflux disease were only associated with increased exace

296 ts a potential biomarker for extraesophageal reflux disease when detected in airways, however a direc

297 Except for gastroesophageal reflux disease, which showed a higher resolution rate af

298 Patients with gastroesophageal reflux disease who have a partial response to proton-pum

299 isits annually, followed by gastroesophageal reflux disease, with 4.5 million visits.

300 (BEAC) is a complication of gastroesophageal reflux disease, with no effective chemotherapy and poor